Ad hoc: Positive Phase II data for P2X3 antagonist in patients with refractory chronic cough




  • Evotec SE announced today that the Company has been informed by Bayer about positive Phase IIa results from a study surveying the safety, efficacy and dosage of the compound BAY1817080 in refractory chronic cough.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-positive-phase-ii-data-for-p2x3-antagonist-in-patients-with-refractory-chronic-cough-5835

    Du magst vielleicht auch